Filing Details
Xilio Therapeutics, Inc. (NASDAQ:XLO) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:XLO
Xilio Therapeutics, Inc. (XLO) Files Quarterly Report for Q0
Xilio Therapeutics, Inc. (NASDAQ:XLO) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
At publication ·
What changed
Xilio Therapeutics, Inc. (NASDAQ:XLO) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Xilio Therapeutics, Inc. (NASDAQ:XLO) filed its quarterly report (Form 10-Q) with the SEC on August 12, 2026.
- The company's stock trades at $9.05 with a market capitalization of $37.6 million.
- The 10-Q filing contains unaudited financial statements and management commentary on recent performance, including updated risk factors and changes in business conditions.
Market Context
Xilio Therapeutics, Inc.'s stock currently trades at $9.05 with a market capitalization of $37.6M.
The 10-Q provides Xilio Therapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Xilio Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View XLO Stock Page
Frequently Asked Questions
Where can I read XLO's SEC filings?
Browse all filings on our XLO SEC filings page.
What types of SEC filings does Xilio Therapeutics, Inc. file?
Public companies like Xilio Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.